AGC Biologics, a prominent Contract Development and Manufacturing Organization (CDMO) in the biopharmaceutical industry, has bolstered its executive leadership by appointing Dr. Christoph Winterhalter as Chief Business Officer. With three decades of experience under his belt, Winterhalter will oversee crucial aspects of the company’s operations, including corporate strategy, business development, new business initiatives, and global marketing for AGC Biologics’ CDMO network.
Winterhalter’s impressive track record in the life science industry encompasses creating strategies for sustainable and profitable business growth, building and leading skilled global teams, spearheading business development and marketing initiatives, and fostering strategic partnerships with major pharmaceutical and biopharmaceutical companies. Prior to his promotion, he served as the Senior Vice President of Business Development for Europe, the Middle East, and Africa (EMEA) at AGC Biologics.
Patricio Massera, CEO of AGC Biologics, expressed confidence in Winterhalter’s appointment, stating, ‘Throughout his career, Christoph has developed a unique combination of technical knowledge and the ability to create business growth for life science organizations.’ Massera highlighted Winterhalter’s proven leadership and vision, which will be instrumental in creating value for the business through corporate development, strategic partnerships, and sales and marketing initiatives. ‘This experience will be crucial for AGC Biologics’ growth, and I am confident he will positively impact our global teams as we strive to achieve our purpose: to bring hope to life by enabling life-changing therapies for patients around the globe,’ Massera added.
Winterhalter joined AGC Biologics in 2018 and has significantly contributed to the company’s growth over the past six years. Before that, he served as the Senior Vice President of Global Business Development for the CDMO Rentschler Biopharma, where he guided the company’s global sales and development strategy and created strategic manufacturing alliances with leading global biopharmaceutical companies. During his tenure at Rentschler, Winterhalter played a pivotal role in tripling the company’s top-line sales numbers.
In his new role as Chief Business Officer, Winterhalter expressed enthusiasm for taking on more responsibility at a company dedicated to supporting biopharmaceutical companies developing important treatments to help patients worldwide. ‘I look forward to partnering with the rest of the executive team, contributing my expertise to advance AGC Biologics’ business goals, and working side-by-side with our partners to bring their innovative biopharmaceuticals all the way to market,’ he said.
To learn more about AGC Biologics and its global CDMO services, visit www.agcbio.com.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is AGC Biologics Appoints Dr. Christoph Winterhalter as Chief Business Officer.